ALM-412 is under clinical development by Almirall and currently in Phase I for Familial Adenomatous Polyposis.

Diagnosis: Familial adenomatous polyposis with mental retardation, caused by an interstitial deletion of the long arm of chromosome 5 encompassing the APC (adenomatous polyposis coli) tumor ...

A free fatty acid form of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) reduces both the size and number of polyps in patients with familial adenomatous polyposis (FAP ...

Have you been diagnosed with Adrenal tumour? Here are the top 10 signs that will help you know if its cancerous or not!

Ladenburg raised the firm’s price target on Biodexa Pharmaceuticals (BDRX) to $18 from $8 and keeps a Buy rating on the shares. The company ...

Sirolimus is under clinical development by Biodexa Pharmaceuticals and currently in Phase II for Prostate Cancer. According to GlobalData, ...

The rights come with $17M in non-dilutive funding for a pivotal Phase 3 study of the drug in the treatment of Familial Adenomatous Polyposis, or FAP, a genetic orphan disease that can cause ...